October 4, 2016

Brainshake looks for regulatory approval and internationalisation

Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods.
Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods.
Brainshake

Finnish blood analysis company Brainshake has raised two million euros in Series B funding.

The news comes on the heels of the recent announcement that the company had closed 3.5 million euros in Series A funding. This brings the total amount it has raised in the past two years to 7.5 million euros.

The capital injection sees Finnish growth company accelerator TJP Consulting joining Brainshake as a strategic partner in building the company’s global operations.

“The disruptive power of Brainshake’s technology relies in extensive scientific background and scalability allowing the blood analysis to be used in routine healthcare,” says TJP consulting chairman Tuomas Poskiparta. “…Brainshake has a unique position to disrupt routine blood sample analysis globally in chronic diseases, such as diabetes and CVD.”

Share: